Improving the Affordability of Anticancer Medicines Demands Evidence-Based Policy Solutions.

Franzen, Nora; Romagnoli, Giorgia; Ziegler, Andreas; Retèl, Valesca P; Offerman, Theo J S; van Harten, Wim H

Franzen, Nora; Romagnoli, Giorgia; Ziegler, Andreas; Retèl, Valesca P; Offerman, Theo J S; van Harten, Wim H.

Afiliación

Franzen N; The Netherlands Cancer Institute, Department of Psychosocial Research and Epidemiology, Amsterdam, the Netherlands.
Romagnoli G; University of Twente, Department of Health Technology and Services Research, Enschede, the Netherlands.
Ziegler A; University of Amsterdam, Center for Research in Experimental Economics and Political Decision Making, Amsterdam, the Netherlands.
Retèl VP; University of Amsterdam, Center for Research in Experimental Economics and Political Decision Making, Amsterdam, the Netherlands.
Offerman TJS; The Netherlands Cancer Institute, Department of Psychosocial Research and Epidemiology, Amsterdam, the Netherlands.
van Harten WH; University of Twente, Department of Health Technology and Services Research, Enschede, the Netherlands.

Cancer Discov ; 12(2): 299-302, 2022 02.

Article en En | MEDLINE | ID: mdl-35086923

Asunto(s)

Antineoplásicos/economía; Costos y Análisis de Costo; Necesidades y Demandas de Servicios de Salud; Medicina Basada en la Evidencia; Humanos; Políticas; Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Costos y Análisis de Costo / Necesidades y Demandas de Servicios de Salud / Antineoplásicos Tipo de estudio: Guideline / Health_economic_evaluation Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Cancer Discov Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google